Company Filing History:

10 out of 43

Vernalis Research Limited

patents

5 out of 4,945

Hoffmann-la Roche Inc.

patents

3 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2008

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7323466 - Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity (2008-01-29),

2. 7253281 - Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles (2007-08-07),

3. 7098337 - 1,2,3,4,9,9a-hexahydro-2,4a,5-triaza-fluorene and 1,2,3,4-tetrahydro-2,4a,5-triaza-fluorene derivatives (2006-08-29),

4. 7022707 - Piperazine derivatives (2006-04-04),

5. 6933387 - Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles (2005-08-23),

6. 6706750 - Indole derivatives process for their preparation, pharmaceutical compositions containing them and their medicinal application (2004-03-16),

7. 6610685 - Fused indole derivatives (2003-08-26),

8. 6583134 - Aza- indolyl derivatives for treating obesity (2003-06-24),

9. 6552062 - Indazole derivatives with 5-HT2 receptor activity (2003-04-22),

10. 6479534 - Indoline derivatives and method of treating obesity (2002-11-12),

11. 6433175 - Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists (2002-08-13),

12. 6380238 - Indoline derivatives as 5-HT2B and or 5-HTC receptor ligands (2002-04-30),

13. 6365598 - Pyrroloquinolines for treatment of obesity (2002-04-02),

Title: The Innovations of Jonathan Mark Bentley

Introduction

Jonathan Mark Bentley is a notable inventor based in Wokingham, GB. He holds an impressive portfolio of 13 patents, showcasing his contributions to the field of medicinal chemistry. His work primarily focuses on developing innovative compounds for the treatment of various health conditions.

Latest Patents

Among his latest patents, Bentley has developed morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity. This invention refers to chemical compounds of a specific formula, which can be utilized in the preparation of medicaments. Another significant patent involves anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles. This invention is directed towards derivatives that can be used in pharmaceutical preparations for treating or preventing disorders of the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity, and sleep apnea.

Career Highlights

Throughout his career, Bentley has worked with prominent companies such as Vernalis Research Limited and Hoffmann-La Roche Inc. His experience in these organizations has significantly contributed to his expertise in pharmaceutical research and development.

Collaborations

Bentley has collaborated with notable colleagues, including Jonathan Richard Anthony Roffey and David Reginald Adams. These partnerships have likely enhanced his innovative capabilities and broadened his research horizons.

Conclusion

Jonathan Mark Bentley's contributions to medicinal chemistry through his patents and collaborations highlight his significant role as an inventor. His work continues to impact the development of treatments for various health conditions.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com